If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

New York, New York-- (Newsfile Corp. - November 29, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...

Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

On Wednesday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.4 which represents a decrease of $-0.03 or -0.68% from the prior close of $4.43. The stock opened at $4.44 and touched a low ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – ...

Insiders who acquired US$775.1k worth of Humacyte, Inc.'s (NASDAQ:HUMA) stock at an average price of US$6.64 in the past 12 months may be dismayed by the recent 17% price decline. Insiders ...